Mankind Pharma has broadened its presence in the pet nutrition space with the launch of PetStar Delight, marking the brand’s foray into the cat food segment. The new range builds on the success of PetStar dog food, introduced in 2022, and reflects the company’s growing focus on comprehensive pet wellness. The expansion arrives at a time when India’s cat food market, currently estimated at around ₹1,500 crore with monthly sales nearing ₹120 crore, is witnessing rapid momentum with an annual growth rate of 18–20 percent.
PetStar Delight has been developed to support overall feline health through a blend of functional ingredients such as cranberry to promote urinary health, turmeric to aid immunity and digestion, and taurine for essential organ function. Manufactured in Thailand under strict quality controls, the range offers a clean label promise with no artificial colours or preservatives. T
he product comes in three flavours — salmon, tuna and ocean fish — tailored to suit varied feline tastes, and is designed to meet the nutritional demands of kittens and adult cats. The kitten formula contains 32 percent protein and 12 percent fat to support growth between one and twelve months of age, while the adult formula provides 30 percent protein and 10 percent fat for cats older than twelve months.
According to Vice Chairman and Managing Director Rajeev Juneja, the introduction of PetStar Delight reflects the evolving needs of Indian pet parents and reinforces the company’s mission to provide quality and scientifically backed nutrition. Dr Piyush Prashant, who heads the Pet Food Division, highlighted that the expertise gained from the development of UK-manufactured PetStar dog food and specialised diets is now being applied to cat nutrition. Each recipe incorporates targeted ingredients including beta-glucans and MOS for digestive strength, natural fibre for hairball control, salmon oil for brain development, choline for nerve support and yucca extract to minimise stool odour, offering a well-rounded solution for concerns commonly reported by cat owners.
Available in 400-gram, 1-kilogram and 2.8-kilogram packs, PetStar Delight is priced at ₹399 for the kitten variant and ₹375 for the adult variant in the 1-kilogram size, and will be rolled out nationwide. With this launch, Mankind Pharma strengthens its footprint in India’s fast-expanding pet care industry, supported by a strong distribution network and a brand reputation built on quality and trust.
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of India’s largest pharmaceutical companies, with a strong focus on the domestic market and a widespread Pan-India presence. The company operates across the pharmaceutical formulations and consumer healthcare segments with a mission to deliver high-quality products at affordable prices.
Mankind is a key player in the Indian pharmaceutical sector with a presence in both acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynecology, VMN, and respiratory segments. The company continues to expand its footprint in chronic therapies as part of its long-term strategy.
In the consumer healthcare domain, Mankind has built a strong portfolio across categories such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne products, among others. Many of its brands hold leading market positions in their respective categories. The acquisition of Bharat Serums and Vaccines Limited has further strengthened Mankind Pharma’s leadership, particularly in the women’s health segment.
The company’s distribution network is supported by a field force of over 17,700 professionals and connects with more than 500,000 doctors across both urban and rural regions. Mankind operates 32 manufacturing facilities in India, producing a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow-fill-seal products, soft and hard gelatin capsules, eye drops, creams, contraceptives, and other OTC offerings. Mankind also maintains a strong focus on research and development, supported by six dedicated R&D centers and a team of more than 730 scientists, ensuring continuous innovation and product advancement.
